EPISODE · Dec 30, 2025 · 38 MIN
Ep. 341 - BioCentury's '25-'26 Picks. Plus: BioMarin & Biotech ICYMI
from BioCentury This Week · host BioCentury
This past year was an inflection point for biotech: The markets woke up, M&A and China had strong showings, drug development offered key trends, and new leadership at FDA shuffled the regulatory deck. On the latest BioCentury This Week podcast, BioCentury’s analysts make their picks for the biggest biopharma readouts, deals and regulatory and policy moves of 2025 and what they are forecasting for the year ahead.The analysts also recap biotech highlights of the past two weeks, including the $4.8 billion takeout of Amicus Therapeutics by BioMarin Pharmaceutical.View full story: https://www.biocentury.com/article/657933#BiotechOutlook2026 #BiopharmaTrends #BiotechMA #FDALeadership #ChinaBiotech00:00 - Introduction 02:31 - BioMarin's $4.8B Amicus Deal06:07 - Year-end Biotech Highlights16:37 - Analyst Picks and Predictions30:01 - Policy and Regulatory LandscapeTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text
What this episode covers
This past year was an inflection point for biotech: The markets woke up, M&A and China had strong showings, drug development offered key trends, and new leadership at FDA shuffled the regulatory deck. On the latest BioCentury This Week podcast, BioCentury’s analysts make their picks for the biggest biopharma readouts, deals and regulatory and policy moves of 2025 and what they are forecasting for the year ahead. The analysts also recap biotech highlights of the past two weeks, including t...
NOW PLAYING
Ep. 341 - BioCentury's '25-'26 Picks. Plus: BioMarin & Biotech ICYMI
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 3, 2026 ·44m
Feb 21, 2026 ·30m
Jan 2, 2026 ·47m